Stock Events

Stock Events

Biofrontera 

€2.56
0
+€0.03+1.19% Monday 06:13

Statistics

Day High
2.56
Day Low
2.56
52W High
2.76
52W Low
1.33
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q1 2023
Q4 2025
Next
-0.3
-0.06
0.18
0.41
Expected EPS
-0.09739350000000001
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow B8FK.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Davis Select U.S. Equity
DUSA
Mkt Cap0
DUSA Pharmaceuticals, Inc. is a direct competitor in the dermatology space, specifically in photodynamic therapy products, similar to Biofrontera's Ameluz for treating actinic keratosis.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. has a diversified portfolio that includes treatments for various conditions, including skin-related diseases, potentially competing with Biofrontera's dermatological products.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc. is a global pharmaceutical company with a broad product line that includes treatments for skin conditions, making it a competitor to Biofrontera.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson offers a wide range of healthcare products, including pharmaceuticals and personal care products for skin health, competing with Biofrontera's dermatological treatments.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie Inc., having acquired Allergan, has strengthened its dermatology portfolio, making it a stronger competitor to Biofrontera in the skin care and treatment market.
Novartis
NVS
Mkt Cap297.35B
Novartis International AG has a significant presence in the dermatology market with products that treat a range of skin conditions, competing with Biofrontera's therapeutic offerings.

About

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Show more...
CEO
Dr. Hermann Luebbert Ph.D.
Employees
92
Country
United States
ISIN
DE000A4BGGM7

Listings

MU
DE
B8FK.MU
XNAS
US
BFRI
STU
DE
AI10.STU
STU
DE
B8FK.STU

0 Comments

Share your thoughts

FAQ

What is Biofrontera stock price today?▼
The current price of B8FK.MU is €2.56 EUR — it has increased by +1.19% in the past 24 hours. Watch Biofrontera stock price performance more closely on the chart.
What is Biofrontera stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Biofrontera stocks are traded under the ticker B8FK.MU.
Is Biofrontera stock price growing?▼
B8FK.MU stock has fallen by -0.78% compared to the previous week, the month change is a -1.16% fall, over the last year Biofrontera has showed a +7.11% increase.
When is the next Biofrontera earnings date?▼
Biofrontera is going to release the next earnings report on May 08, 2026.
What were Biofrontera earnings last quarter?▼
B8FK.MU earnings for the last quarter are 0.41 EUR per share, whereas the estimation was 0.17 EUR resulting in a +146.15% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Biofrontera have?▼
As of April 16, 2026, the company has 92 employees.
In which sector is Biofrontera located?▼
Biofrontera operates in the Health & Wellness sector.
When did Biofrontera complete a stock split?▼
Biofrontera has not had any recent stock splits.
Where is Biofrontera headquartered?▼
Biofrontera is headquartered in Woburn, United States.